HTLV-1相关葡萄膜炎患者的全身性疾病
该研究回顾性调查200例HTLV-1相关葡萄膜炎(HAU)患者的病历及邮寄问卷,分析其全身性疾病发生情况。HAU平均发病年龄49岁,从HAU发病起总计1627人年,出现2例成人T细胞白血病(ATL)和26例HTLV-1相关脊髓病/热带痉挛性截瘫(HAM/TSP);45例甲状腺功能亢进均先于HAU发病。作者认为伴HAU的HTLV-1携带者发生HAM/TSP可能比一般携带者更频繁,接受甲亢治疗的HTLV-1携带者可能易发生HAU。
要点
- 200例HAU患者中发生2例ATL、26例HAM/TSP,45例甲状腺功能亢进。
- 26例HAM/TSP中13例HAM/TSP先发、11例HAU先发,间隔6个月至6年。
- 45例甲亢均先于HAU发病,2例重启甲巯咪唑治疗后HAU复发。
核心结论
- 伴HAU的HTLV-1携带者发生HAM/TSP可能比一般携带者更频繁。
- 接受甲亢治疗的HTLV-1携带者可能易发生HAU。
研究设计与样本
- 对200例HAU患者的病历进行回顾性调查,并 examine 邮寄问卷结果,以调查全身性疾病的发生情况。
主要发现
- HAU平均发病年龄为49岁,从HAU发病起总计1627人年。
- 共2例ATL:1例在HAU发病时诊断为冒烟型ATL,另1例在HAU发病后4年发生急性型ATL。
- 共26例HAM/TSP:13例HAM/TSP先发生,11例HAU先发生;HAM/TSP与HAU发病间隔为6个月至6年,按HAM/TSP或HAU何者先发分组未见显著差异。
- 甲状腺功能亢进45例,均先于HAU发病;HAU在开始甲巯咪唑治疗后发病,其中2例每次重启甲巯咪唑治疗时HAU均复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) carriers may develop severe systemic diseases, such as adult T cell leukaemia (ATL) or HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). This study aims to investigate systemic diseases of HTLV-1 carriers who had developed HTLV-1-associated uveitis (HAU). METHODS: We investigated the occurrence of systemic diseases in 200 patients with HAU by performing a retrospective investigation of their medical records and examining the results of a postal survey. RESULTS: The mean age of HAU onset was 49 years, and the total person-years from HAU onset was 1627. There were two cases of ATL. Of these, one was diagnosed with smouldering ATL at the time of HAU onset and the other developed acute-type ATL 4 years after HAU onset. There were 26 cases of HAM/TSP; of these, HAM/TSP occurred first in 13 cases and HAU occurred first in 11 cases. The interval between the onset of HAM/TSP and HAU ranged from 6 months to 6 years, with no significant difference observed based on whether HAM/TSP or HAU occurred first. Hyperthyroidism was noted in 45 cases and preceded onset in all cases. HAU onset occurred after starting thiamazole treatment, and in two cases HAU recurred each time thiamazole treatment was restarted. CONCLUSION: HTLV-1 carriers with HAU may develop HAM/TSP more frequently than general carriers. HTLV-1 carriers undergoing treatment for hyperthyroidism may be prone to developing HAU.
引用
- Nakao K, Abematsu N, Sakamoto T, et al. Systemic diseases in patients with HTLV-1-associated uveitis. Br J Ophthalmol. 2017. PMID: 28689168. doi:10.1136/bjophthalmol-2017-310658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。